BIOGEN for BIOGEN
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
1) Advocacy to reform IPAB to ensure patient access to medically necessary therapies. 2) Implementation of biosimilars regulations to support incentives for innovation and second generation therapies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committe |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Taxation/Internal Revenue Code TAX
Support corporate tax policies which protect US research and manufacturing jobs, including issues related to transfer pricing and R&D credit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Medicare/Medicaid MMM
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Copyright/Patent/Trademark CPT
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window. Opposition to inclusion of patent settlements legislation in appropriations bill.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.